ScreenerHero

OGEN Oragenics, Inc.

AMEX · US · Healthcare · Biotechnology · oragenics.com
0.4999USD+3.07%Mkt Cap: 2.26M $P/E: —

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is O…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.26M USD
Enterprise Value-1.68M USD
Revenue (TTM)—
Gross Profit-3.42M USD
Net Income (TTM)-9.84M USD
Revenue/Share—
Last Price0.4999 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.04
PEG-8.96
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.34
EPS (TTM)-2.43
EPS (Forward)-10.80
52W Range
0.46054% of range1.450
52W High1.450 USD
52W Low0.4605 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-118.85%
ROA-97.76%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.25M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-296.15%
Net Debt-3.86M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.03
Current Ratio3.02
Quick Ratio2.12
Book Value/Sh1.41 USD
Cash/Share0.86 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 22, 2018
Splits
Last Split1:30
Split DateJun 3, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.51M
Float4.42M
Insiders1.93%
Institutions3.06%
Short Interest
Short Ratio21.3d
Short % Float17.89%
Short % Out.17.88%
Shares Short806.54K
Short (prev mo.)788.92K
Technical
SMA 500.5132 (-2.6%)
SMA 2000.6452 (-22.5%)
Beta1.26
S&P 52W Chg15.77%
Avg Vol (30d)32.03K
Avg Vol (10d)26.13K
Technical Indicators
RSI (14)49.8
MACD-0.0089
MACD Signal-0.0106
MACD Hist.+0.0018
BB Upper0.5235 USD
BB Middle0.4949 USD
BB Lower0.4663 USD
BB Width11.56%
ATR (14)0.0257 USD
Vol Ratio (20d)0.43x